NICE gives limited backing to Bayer's Xofigo; Merck KGaA criticizes NICE's Erbitux rejection in bowel cancer;

@FiercePharma: Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Baxalta Singapore plant gets FDA OK to produce Advate. Article | Follow @EricPFierce

> U.K. cost-effectiveness watchdogs gave limited backing to Bayer's prostate cancer therapy Xofigo, recommending it only in patients who've already undergone chemotherapy. Report

> Merck KGaA took issue with the National Institute for Health and Care Excellence's (NICE) decision not to recommend its drug Erbitux for previously untreated metastatic colorectal cancer. Report

> The FDA again rejected AMAG Pharmaceuticals' ($AMAG) single-dose version of its hormone injection Makena. Report

Medical Device News

@FierceMedDev: The top women in medical devices 2015. Feature | Follow @FierceMedDev

@VarunSaxena2: RetroSense bags $6M in funding for its viral vector gene therapy candidate for a rare eye condition. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dx Digest: Invitae builds out cancer and epilepsy testing menus; Illumina gets in on autism research. More | Follow @EmilyWFierce

> Diabetes duodenal resurfacing startup Fractyl bumps Series C up to $57M. More

> Teva teams up with University College London for brain imaging study. Story

> Torax Medical earns key reimbursement code for its implant to treat gastric reflux. Article

Biotech News

@FierceBiotech: UCSD team targeting new stress pathway in Alzheimer's program. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: The Brent Saunders argument that he's opposed to R&D is a bit specious. $AGN acquires late-stage assets, avoids discovery. Not anti-research. | Follow @JohnCFierce

> KaloBios is back from the dead after Shkreli swoops in to 'save' its lead drug. Story

> Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy. Article

> Silicon Valley VC shop Andreessen Horowitz sets up $200M bio fund. Report

CRO News

> WuXi lands a lead role in Genomics England's big project. Item

> Parexel touts its IT-enabled R&D services amid company shakeup. Report

> Fast-growing Charles River trades $36M for a drug discovery outfit. Article

> PRA expands in Singapore with eyes on Asian growth. Story

Pharma Manufacturing News

> Merck KGaA JV set to start producing drugs in remote Algerian village. More

> Shortages, shifts in sterile injectable market lead some prices to soar. Story

> Drug distributor recalls anxiety drug after wrong med found in a bottle. Report

> With pharma cargo theft on the rise, Thanksgiving can be a risky holiday. Item

> Hikma says FDA has closed out warning letter for EU injectables plant. Article

Pharma Asia News

> India's Supreme Court wants stricter oversight of MSD, GSK HPV clinical trials. More

> Price controls loom for generic drugs in India next year. Report

> Samsung Bioepis biosimilar may get nod in Europe. Story

> Mundipharma licenses Spectrum's NHL treatment, picks up Japan affiliate. Item

> GSK beefing up vaccine business in India. Article

And Finally... Presidential candidates have offered a variety of proposals to put a lid on drug-price hikes, but none seem likely to work very well, experts say. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.